- Anthera to receive up to $48,000,000 plus future product margin on commercial supply - Zenyaku to reimburse Anthera for a portion of future blisibimod worldwide development costs
- Zenyaku to assume full responsibility for development and associated costs in Japan and potentially other Asian territories in the future - Companies will collaborate on blisibimod development for both IgA Nephropathy ("IgAN") and Systemic Lupus Erythematosus ("Lupus") HAYWARD, Calif.
Acceleron Pharma Inc. (NASDAQ: XLRN), a biopharmaceutical company
focused on the discovery, development and commercialization of novel
protein therapeutics for cancer and rare diseases, today announced it
has been selected for addition to the NASDAQ Biotechnology Index ® (NASDAQ:
NBI), effective Monday, December 22, 2014.
By Simon Clark
A former BlackRock Inc. fund manager has been banned from the U.K. finance industry for "not being fit and proper" because he repeatedly commuted to work in London without buying the correct rail ticket.
Kindred Healthcare, Inc. (“Kindred” or the “Company”) (NYSE:KND) today
announced that it has entered into an incremental joinder to increase
the available credit capacity from $750 million to $900 million under
its senior secured asset-based revolving credit facility (the “ABL
The increase in the borrowing capacity will be effective upon completion
of the Company’s merger with Gentiva Health Services, Inc. (“Gentiva”),
which is expected in the first quarter of 2015.
By Ben Fritz
Movie studio hires lawyer David Boies to put a lid on hacked information
Sony Pictures Entertainment has retained David Boies, one of the nation's most prominent attorneys, in an effort to stop news publications from using stolen documents that have been leaked online.
Pro Forma Adjusted Net Income increased 22.3% year-over-year to $0.24 per share Fee-earning AUM increased 60.6% year-over-year to $4.8 billion Board of Directors expects to declare a $0.30 per share dividend for Q4 2014 in January 2015 Successful IPO sets stage for future growth and diversification
GREENWICH, CT, Dec.
- Operating income of $11.4 million - Adjusted EBITDA(1) of $24.3 million - Year-to-date operating income of $12.3 million - Year-to-date adjusted EBITDA(1) of $45.6 million
- Filed restated results for first and second quarters of 2014 - Company will host conference call on Tuesday, December 16, 2014 HOUSTON , Dec.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.